Quotient (NASDAQ:QTNT) Upgraded at ValuEngine

ValuEngine upgraded shares of Quotient (NASDAQ:QTNT) from a buy rating to a strong-buy rating in a research note published on Tuesday, ValuEngine reports.

A number of other research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Haynes International from a hold rating to a sell rating in a research note on Wednesday, May 8th. BidaskClub cut shares of Zynerba Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, June 26th.

NASDAQ QTNT opened at $10.06 on Tuesday. The business’s fifty day moving average is $9.22. The company has a market capitalization of $669.73 million, a PE ratio of -5.24 and a beta of 0.88. Quotient has a fifty-two week low of $5.52 and a fifty-two week high of $11.15. The company has a current ratio of 4.59, a quick ratio of 3.98 and a debt-to-equity ratio of 72.27.

Quotient (NASDAQ:QTNT) last released its earnings results on Tuesday, May 28th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.03. The firm had revenue of $8.28 million during the quarter, compared to analyst estimates of $7.30 million. As a group, analysts expect that Quotient will post -1.59 EPS for the current year.

In other Quotient news, Director Frederick Hallsworth bought 3,150 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was bought at an average cost of $8.70 per share, for a total transaction of $27,405.00. Following the completion of the transaction, the director now owns 74,398 shares of the company’s stock, valued at approximately $647,262.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Edward Farrell sold 22,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $8.67, for a total transaction of $195,075.00. Following the sale, the president now owns 2,133 shares of the company’s stock, valued at $18,493.11. The disclosure for this sale can be found here. Company insiders own 17.40% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Niemann Capital Management Inc. purchased a new position in shares of Quotient in the first quarter worth $101,000. Resources Investment Advisors Inc. bought a new position in Quotient during the first quarter valued at $105,000. Rehmann Capital Advisory Group bought a new position in shares of Quotient in the first quarter worth about $154,000. Westfield Capital Management Co. LP bought a new position in shares of Quotient in the first quarter worth about $217,000. Finally, Knott David M grew its holdings in shares of Quotient by 1.8% in the first quarter. Knott David M now owns 170,000 shares of the company’s stock worth $1,532,000 after purchasing an additional 3,000 shares during the last quarter. Institutional investors own 63.91% of the company’s stock.

Quotient Company Profile

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Featured Article: Short Selling – Explanation For Shorting Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.